US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Medicines

84.90

0.0000

Volume:- -

Turnover:- -

Market Cap:6.79B

PE:-27.06

High:84.90

Open:84.90

Low:84.90

Close:84.90

Loading ...

Overview Company News Filings

Hitachi Vantara Supports FarmaMondo with Storage Infrastructure to Provide Vital Medicines 24/7

Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

Navigating Risks: Novartis’s Strategic Challenges in Expanding Innovative Medicines Portfolio

Court Orders to Freeze, Seize 3D Medicines' Bank Deposits, Assets Worth 458.5 Million Yuan

MT Newswires Live

Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference

3D Medicines Faces Asset Freeze Amid Civil Proceedings

Truist Securities Adjusts Price Target on Praxis Precision Medicines to $175 From $150, Keeps Buy Rating

MT Newswires Live

Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘This Company Has Never Lost Its Ability To Develop New Medicines’

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

BeOne Medicines Up Over 12%, on Pace for Largest Percent Increase Since April 2023 -- Data Talk

C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology

Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS Scotland

Applied DNA Sciences Advances in Genetic Medicines Market

Press Release: Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Everest Medicines Updates Hong Kong Business Address

Everest Medicines Clarifies Unusual Price, Trading Volume Movements

MT Newswires Live

Everest Medicines Reports Unusual Trading Activity Amid Shareholder Transaction

Revolution Medicines Is Maintained at Buy by UBS

UBS Adjusts Price Target on Revolution Medicines to $71 From $65, Keeps Buy Rating

MT Newswires Live

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MDCO/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MDCO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCO\",,,,,undefined,":{"symbol":"MDCO","market":"US","secType":"STK","nameCN":"Medicines","latestPrice":84.9,"timestamp":1578085200000,"preClose":84.9,"halted":3,"volume":0,"delay":0,"floatShares":74862655,"shares":79948329,"eps":-3.137449,"marketStatus":"Halted","change":0,"latestTime":"06-23 05:29:39 EDT","open":84.9,"high":84.9,"low":84.9,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.137449,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1750685400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":965707200000,"exchange":"NASDAQ","adjPreClose":84.9,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCO\",,,,,undefined,":{"symbol":"MDCO","floatShares":74862655,"roa":"-13.71%","roe":"553.30%","lyrEps":-1.673974,"shares":79948329,"dividePrice":0,"high":84.9,"amplitude":0,"preClose":84.9,"low":84.9,"week52Low":23.15,"pbRate":"178.02","week52High":84.98,"institutionHeld":1.2829,"latestPrice":84.9,"eps":-3.137449,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.137449,"open":84.9,"prevYearClose":84.94},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCO\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2508302454","title":"Hitachi Vantara Supports FarmaMondo with Storage Infrastructure to Provide Vital Medicines 24/7","url":"https://stock-news.laohu8.com/highlight/detail?id=2508302454","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508302454?lang=en_us&edition=fundamental","pubTime":"2025-02-04 21:55","pubTimestamp":1738677300,"startTime":"0","endTime":"0","summary":"The Swiss pharmaceutical company's migration to Hitachi VSP One boosts performance, scalability and sustainability of global business operations. ZURICH, Switzerland and SANTA CLARA Calif., Feb. 4, 2025 /PRNewswire/ -- Hitachi Vantara, the data storage, infrastructure and hybrid cloud management subsidiary of Hitachi, Ltd. , today announced that it has modernized and deployed a next-generation storage solution for FarmaMondo, a global player in the supply of specialty pharmaceuticals. Together with its partner Netability, Hitachi Vantara led the implementation of Virtual Storage Platform One , a next-generation storage platform that will serve as a reliable and efficient basis for international business operations and help FarmaMondo provide its customers with vital medicines around the clock.Upgrade to NVMe technology: VSP One uses the most modern NVMe flash technology which accelerates and provides predictable performance for interactiv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/hitachi-vantara-supports-farmamondo-storage-135500120.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hitachi-vantara-supports-farmamondo-storage-135500120.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HTHIF","MDCO","HTHIY","BK4206"],"gpt_icon":0},{"id":"2508873114","title":"Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa","url":"https://stock-news.laohu8.com/highlight/detail?id=2508873114","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508873114?lang=en_us&edition=fundamental","pubTime":"2025-02-03 19:30","pubTimestamp":1738582200,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Feb. 03, 2025  -- Ocugen, Inc.  , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the European Commission has provided a positive opinion from the European Medicines Agency’s  Committee for Advanced Therapies  for OCU400 Advanced Therapy Medicinal Product  classification. OCU400 is the first gene therapy to enter Phase 3 with a broad retinitis pigmentosa  indication.“Receiving ATMP classification is another significant milestone toward bringing OCU400 to the market in Europe,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. “This designation makes it possible to stay on track with our clinical and commercial strategy and potentially provide this novel modifier gene therapy candidate to all RP patients in the United States  and Europe by 2027.”“We are encouraged by the EMA’s recognition of OCU400 as the Phase 3 liMeliGhT clinical trial advances,”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ocugen-announces-positive-opinion-european-113000968.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0031619046.USD","LU1974910355.USD","BK4520","MDCO","OCGN","CAT","LU0942090050.USD","BK4149","IE00BD6J9T35.USD","LU1064131342.USD","BK4597","IE00BSNM7G36.USD","BK4588","ATMP","LU2264538146.SGD","IE00B19Z4B17.USD","BK4568","BK4532","BK4139","LU1917777945.USD","IE00B7SZL793.SGD","BK4157","IE00B66KJ199.SGD","BK4585","BK4563","LU2237438978.USD","LU1988902786.USD","LU0868494617.USD","BK4516","LU0868494708.USD","MAA","AEIS","LU2023250504.SGD","LU2106854487.HKD","BK4215"],"gpt_icon":0},{"id":"2508112949","title":"Navigating Risks: Novartis’s Strategic Challenges in Expanding Innovative Medicines Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2508112949","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508112949?lang=en_us&edition=fundamental","pubTime":"2025-02-01 14:00","pubTimestamp":1738389636,"startTime":"0","endTime":"0","summary":"Novartis AG (NVS) has disclosed a new risk, in the Corporate Activity and Growth category. Novartis AG faces significant risks in its strategy of l...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/navigating-risks-novartiss-strategic-challenges-in-expanding-innovative-medicines-portfolio?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/navigating-risks-novartiss-strategic-challenges-in-expanding-innovative-medicines-portfolio?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0211331839.USD","NVS","BK4007","BK4585","IE0009355771.USD","IE00BJJMRZ35.SGD","MDCO","IE00B4R5TH58.HKD","BK4578","BK4532","BK4588","IE0002141913.USD"],"gpt_icon":0},{"id":"2507646638","title":"Court Orders to Freeze, Seize 3D Medicines' Bank Deposits, Assets Worth 458.5 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2507646638","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507646638?lang=en_us&edition=fundamental","pubTime":"2025-01-30 18:50","pubTimestamp":1738234257,"startTime":"0","endTime":"0","summary":"3D Medicines  said the Qingdao Intermediate People's Court of Shandong Province, China ordered the freezing of bank deposits amounting to 458.5 million yuan or a seizure of assets of equivalent value belonging to the members of the group, a Hong Kong bourse filing from last Friday said.The court order was made at the request of Qingdao Hainuo Investment Development.The company said it did not receive any statement of claim underlying the civil ruling and the seizure of assets is a compulsory measure taken by the court.The company has applied to revoke the civil ruling and will try to resolve the dispute as soon as possible.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","BK1161","01244"],"gpt_icon":0},{"id":"2507663054","title":"Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507663054","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507663054?lang=en_us&edition=fundamental","pubTime":"2025-01-30 05:05","pubTimestamp":1738184700,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Jan.  29, 2025  (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicte","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/29/3017572/0/en/Revolution-Medicines-to-Participate-in-the-Guggenheim-Securities-SMID-Cap-Biotech-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ199S13.USD","BK4141","RVMD","MDCO","LU1861215975.USD","LU1861220033.SGD","LU1720051108.HKD","LU1854103824.USD","LU0724618433.USD","LU0348723411.USD","LU1861214812.USD","SMID","LU1854104046.USD","LU0124384867.USD","BK4011","BK4512","LU2360107325.USD","LU2357305700.SGD","BK4139","BK4588","LU1720051017.SGD","BK4585","ON","LU1978683503.SGD","LU2298322129.HKD","LU1548497426.USD","LU1861219969.SGD","IE00BD6J9T35.USD"],"gpt_icon":0},{"id":"2505686104","title":"3D Medicines Faces Asset Freeze Amid Civil Proceedings","url":"https://stock-news.laohu8.com/highlight/detail?id=2505686104","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505686104?lang=en_us&edition=fundamental","pubTime":"2025-01-24 23:08","pubTimestamp":1737731337,"startTime":"0","endTime":"0","summary":"3D Medicines, Inc. ( ($HK:1244) ) just unveiled an announcement. 3D Medicines Inc. has announced that a civil ruling has been issued by the Qingdao...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/3d-medicines-faces-asset-freeze-amid-civil-proceedings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/3d-medicines-faces-asset-freeze-amid-civil-proceedings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"gpt_icon":0},{"id":"2505622404","title":"Truist Securities Adjusts Price Target on Praxis Precision Medicines to $175 From $150, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2505622404","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505622404?lang=en_us&edition=fundamental","pubTime":"2025-01-21 20:45","pubTimestamp":1737463512,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines (PRAX) has an average rating of buy and mean price target of $165.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","PRAX"],"gpt_icon":0},{"id":"2504465786","title":"Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘This Company Has Never Lost Its Ability To Develop New Medicines’","url":"https://stock-news.laohu8.com/highlight/detail?id=2504465786","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504465786?lang=en_us&edition=fundamental","pubTime":"2025-01-19 19:17","pubTimestamp":1737285459,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar.In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc.  stands against the other stocks on Jim Cramer's radar.Jim Cramer, host of Mad Money, recently emphasized the importance of long-term investing, urging investors to focus on the growth prospects of certain pharmaceutical stocks while also answering callers’ questions about certain stocks. Cramer acknowledged that stocks often experience cyclical trends, with some sectors falling out of favor temporarily.“Look, stocks go in and out of style in the Wall Street fashion show. Whole sectors wallow at times. Right now, healthcare’s in some sort of doghouse the likes of which I’ve never seen.”READ ALSO Jim Cramer’s Lightning Round: 7 Stocks Under the Spotlight and Jim Cramer is Watching These 8 Stocks. A pharmacist in a lab coat carefully analyzing a vial of medicine f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jim-cramer-regeneron-pharmaceuticals-inc-111739382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QLD","USAW.SI","ABIL","USJW.SI","LU2023250504.SGD","MNQmain","LU0823416689.USD","QID","LU0053666078.USD","NQmain","LU0320765992.SGD","LU0109394709.USD","LU2089984988.USD","MDCO","BK4585","LU2362541273.HKD","LU1974910355.USD","BK4139","TQQQ","BK4588","PSQ","TSYW.SI","LU0114720955.EUR",".IXIC","LU0058720904.USD","REGN","LU0889565916.HKD","LU0289739699.SGD","LU2362540622.SGD","LU2362541513.USD","NVIW.SI","LU2106854487.HKD","LU2468319806.SGD","LU2237438978.USD","SQQQ","LU1917777945.USD","LU0882574055.USD"],"gpt_icon":1},{"id":"2503677942","title":"Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2503677942","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503677942?lang=en_us&edition=fundamental","pubTime":"2025-01-16 05:05","pubTimestamp":1736975100,"startTime":"0","endTime":"0","summary":"- Duchenne: Dosed four patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 - - FA: First-in-","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/15/3010436/0/en/Solid-Biosciences-Outlines-Key-Priorities-for-Advancing-Diversified-Neuromuscular-and-Cardiac-Development-Pipeline-and-Establishing-Leadership-in-Precision-Genetic-Medicines.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106831901.USD","BK4539","LU2023251221.USD","BK4139","LU0971096721.USD","LU1363072403.SGD","FA","LU0006306889.USD","LU2089283258.USD","LU1989772923.USD","LU0158827781.USD","LU0912757837.SGD","LU2347655156.SGD","BK4127","LU0098860793.USD","LU0267386448.USD","BK4130","BK4516","LU2089284900.SGD","LU0106261372.USD","LU0225283273.USD","BK4585","BK4534","LU2111349929.HKD","LU1162221912.USD","BK4535","LU0314104364.USD","BK4590","IE00BKVL7J92.USD","LU2271345857.HKD","BK4121","MDCO","LU1732799900.SGD","LU1720051108.HKD","BK4144","LU2357305700.SGD","CTA","BK4023","LU1732800096.USD","SLDB","LU1989772840.SGD","BK4588","BK4504","GENE","LU0795875169.SGD","IE00BZ1G4Q59.USD","IDN","LU1074936037.SGD","GLP","LU0795875086.SGD"],"gpt_icon":0},{"id":"2503507201","title":"BeOne Medicines Up Over 12%, on Pace for Largest Percent Increase Since April 2023 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2503507201","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503507201?lang=en_us&edition=fundamental","pubTime":"2025-01-15 02:30","pubTimestamp":1736879400,"startTime":"0","endTime":"0","summary":"BeOne Medicines Ltd Sponsored ADR  is currently at $207.09, up $22.48 or 12.18%. --Would be highest close since Dec. 9, 2024, when it closed at $207.62. --On pace for largest percent increase since April 6, 2023, when it rose 12.48%. --Currently up two consecutive days; up 17.19% over this period. --Down 48.63% from its all-time closing high of $403.14 on Sept. 17, 2021. --Down 15.83% from its 52-week closing high of $246.04 on Oct. 4, 2024. --Up 59.89% from its 52-week closing low of $129.52 on April 19, 2024. --Traded as high as $207.21; highest intraday level since Dec. 9, 2024, when it hit $211.00. --Up 12.24% at today's intraday high; largest intraday percent increase since March 13, 2024, when it rose as much as 12.85%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCO","ONC","BK4139"],"gpt_icon":0},{"id":"2503546521","title":"C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2503546521","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503546521?lang=en_us&edition=fundamental","pubTime":"2025-01-14 20:00","pubTimestamp":1736856000,"startTime":"0","endTime":"0","summary":"Cemsidomide Data Presented at American Society of Hematology (ASH) Annual Meeting Support Best-in-Class Profile; Program Advancing to Next Phase of Clinical Development in Multiple Myeloma and Non-Hod","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/14/3009167/0/en/C4-Therapeutics-Announces-2025-Milestones-Across-Clinical-Portfolio-of-Degrader-Medicines-Pursuing-Targets-of-High-Unmet-Need-in-Oncology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2463526074.USD","BK4213","CRC","LENZ","CCCC","BK4563","LU0456854461.SGD","QD","MDCO","ASH","BK4139","BK4109","BK4503","BK4166","LU0266512127.USD"],"gpt_icon":0},{"id":"2503519750","title":"Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS Scotland","url":"https://stock-news.laohu8.com/highlight/detail?id=2503519750","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503519750?lang=en_us&edition=fundamental","pubTime":"2025-01-14 14:00","pubTimestamp":1736834400,"startTime":"0","endTime":"0","summary":"Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE  in Duchenne Muscular Dystrophy Patients in NHS Scotland. AGAMREE is approved by MHRA for treating Duchenne muscular dystrophy  in patients 4 years of age and older in UK. Pratteln, Switzerland, January 14, 2025 – Santhera Pharmaceuticals  announces that the Scottish Medicines Consortium  has published recommendations that AGAMREE  is accepted for use within NHS Scotland for the treatment of Duchenne muscular dystrophy  in patients 4 years of age and older.Dario Eklund, CEO of Santhera, commented: \"I am delighted that the team has secured this latest approval, which will ensure Scottish patients can benefit from this important treatment for DMD. We will work closely with NHS Scotland, along with all the key regulatory and health authorities in all our approved markets, to ensure patients have access to AGAMREE.”AGAMREE was the first medicinal product for DMD to have received approval in ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/santhera-receives-positive-recommendation-scottish-060000414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MDCO","SMC","BK4139","BK4144","SPHDF"],"gpt_icon":0},{"id":"2503001933","title":"Applied DNA Sciences Advances in Genetic Medicines Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2503001933","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503001933?lang=en_us&edition=fundamental","pubTime":"2025-01-13 22:15","pubTimestamp":1736777717,"startTime":"0","endTime":"0","summary":"Applied DNA Sciences ( ($APDN) ) has issued an update. Applied DNA Sciences has completed significant milestones with its Linea IVT and LineaDNA pl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/applied-dna-sciences-advances-in-genetic-medicines-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/applied-dna-sciences-advances-in-genetic-medicines-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GENE","APDN","BK4109","BK4121","BK4139","BK4583","MDCO","DNA"],"gpt_icon":0},{"id":"2503421312","title":"Press Release: Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities","url":"https://stock-news.laohu8.com/highlight/detail?id=2503421312","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503421312?lang=en_us&edition=fundamental","pubTime":"2025-01-13 10:00","pubTimestamp":1736733600,"startTime":"0","endTime":"0","summary":"Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028. Study 1 of Essential3 program for ulixacaltamide in essential tremor  on track for Q1 2025 interim analysis; NDA filing for ulixacaltamide expected in 2025. Mr. Souza continued, \"We are now well positioned for a readout-rich 2025, with results anticipated for ulixacaltamide in the Essential3 program in ET followed by our first NDA filing, as well as topline results for vormatrigine from the RADIANT study in focal onset seizures  and generalized epilepsy, and the POWER1 study in FOS. We are also thrilled to have received a third rare pediatric drug designation  for relutrigine in Dravet Syndrome, and with strong interest in cohort 2 of the EMBOLD study, we expect to file the NDA in 2026. With regulatory feedback on the elsunersen program, we expect to initiate the pivotal trial in the first half of 2025. We are sufficiently funded to adv","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","03160","BK4555","BK4519","LU1093756168.USD","LU1093756325.SGD","ET","BK4588","LU0061475181.USD","IE00B19Z3581.USD","PRAX","IE00B7SZLL34.SGD","BK4144","BK4105","AES","TM","IE0002270589.USD","BK4561","BK4099","IE00B19Z3B42.SGD","BK4590","MDCO","BK4200","BK4135","CNS","ASO","BK4585","BK4139"],"gpt_icon":0},{"id":"2502852260","title":"Everest Medicines Updates Hong Kong Business Address","url":"https://stock-news.laohu8.com/highlight/detail?id=2502852260","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502852260?lang=en_us&edition=fundamental","pubTime":"2025-01-10 20:09","pubTimestamp":1736510985,"startTime":"0","endTime":"0","summary":"Everest Medicines Ltd. ( ($HK:1952) ) has issued an announcement. Everest Medicines Limited has announced a change in their principal place of busi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/everest-medicines-updates-hong-kong-business-address?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/everest-medicines-updates-hong-kong-business-address?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"gpt_icon":0},{"id":"2502905805","title":"Everest Medicines Clarifies Unusual Price, Trading Volume Movements","url":"https://stock-news.laohu8.com/highlight/detail?id=2502905805","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502905805?lang=en_us&edition=fundamental","pubTime":"2025-01-09 11:01","pubTimestamp":1736391679,"startTime":"0","endTime":"0","summary":"Everest Medicines  reported unusual price and trading volume fluctuations on Wednesday, owing to a block trade by the controlling shareholder of the company, according to a Thursday filing with the Hong Kong bourse.The company clarified that CBC Group sold 17.1 million shares via a block trade to international investors. It still retains over 34% ownership in Everest Medicines. Executives confirmed that they did not sell any shares, and the event has no bearing on the company's operations or financial position.The company's shares were down by over 2%.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","01952","1D1.SI","BK6030","BK1574","BK1583","BK1161","BK6505"],"gpt_icon":0},{"id":"2502822120","title":"Everest Medicines Reports Unusual Trading Activity Amid Shareholder Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2502822120","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502822120?lang=en_us&edition=fundamental","pubTime":"2025-01-09 07:07","pubTimestamp":1736377648,"startTime":"0","endTime":"0","summary":"The latest update is out from Everest Medicines Ltd. ( ($HK:1952) ). Everest Medicines Limited, listed on the Hong Kong Stock Exchange, experienced...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/everest-medicines-reports-unusual-trading-activity-amid-shareholder-transaction?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/everest-medicines-reports-unusual-trading-activity-amid-shareholder-transaction?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"gpt_icon":0},{"id":"2501776445","title":"Revolution Medicines Is Maintained at Buy by UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2501776445","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501776445?lang=en_us&edition=fundamental","pubTime":"2025-01-08 23:17","pubTimestamp":1736349420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2025 10:17 ET (15:17 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCO","RVMD"],"gpt_icon":0},{"id":"2501206327","title":"UBS Adjusts Price Target on Revolution Medicines to $71 From $65, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2501206327","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501206327?lang=en_us&edition=fundamental","pubTime":"2025-01-08 22:02","pubTimestamp":1736344947,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) has an average rating of buy and mean price target of $73.43, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","RVMD"],"gpt_icon":0},{"id":"2501602267","title":"Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2501602267","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501602267?lang=en_us&edition=fundamental","pubTime":"2025-01-07 05:05","pubTimestamp":1736197500,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Jan.  06, 2025  (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicte","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/06/3004957/0/en/Revolution-Medicines-to-Present-at-43rd-Annual-J-P-Morgan-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1074936037.SGD","LU1978683503.SGD","BK4127","ON","MDCO","LU2023251221.USD","BK4516","LU2357305700.SGD","HCSG","LU2089283258.USD","IE00BKVL7J92.USD","LU0971096721.USD","LU1720051017.SGD","LU1989772840.SGD","BK4581","LU1548497426.USD","LU1989772923.USD","RVMD","LU0795875086.SGD","LU1162221912.USD","BK4141","LU2089284900.SGD","LU1854104046.USD","BK4137","LU0106831901.USD","BK4512","BK4585","LU0225283273.USD","LU0158827781.USD","LU1720051108.HKD","IE00BZ1G4Q59.USD","LU0124384867.USD","LU2028103732.USD","LU1732799900.SGD","BK4588","LU0106261372.USD","LU0320765646.SGD","LU1363072403.SGD","LU0158827948.USD","BK4139","LU0098860793.USD","LU0724618433.USD","LU2271345857.HKD","LU1732800096.USD","LU0006306889.USD","LU2360107325.USD","IE00BD6J9T35.USD","LU1854103824.USD","LU2347655156.SGD","BK4534"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":7,"totalSize":153,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCO\",params:#limit:5,,,undefined,":[{"date":"2019-10-30","symbol":"MDCO","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/09","expectedEps":-0.84,"defaultRemindTime":1572422400000,"name":null,"time":"Pre-Market","dateTimestamp":1572408000000,"actualEps":null},{"date":"2019-07-24","symbol":"MDCO","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/06","expectedEps":-0.66,"defaultRemindTime":1563955200000,"name":null,"time":"Pre-Market","dateTimestamp":1563940800000,"actualEps":-0.67},{"market":"US","date":"2019-04-25","symbol":"MDCO","fiscalQuarterEnding":"2019/03","expectedEps":-0.71,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1556164800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2019-02-27","symbol":"MDCO","fiscalQuarterEnding":"2018/12","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1551243600000,"reportTimeType":"pre","actualEps":-0.67},{"market":"US","date":"2018-11-08","symbol":"MDCO","fiscalQuarterEnding":"2018/09","expectedEps":-0.48,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1541653200000,"reportTimeType":"pre","actualEps":-0.7}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCO\",market:\"US\",delay:false,,,undefined,":{}}}